Hasan Volkan Ege

Dr. Hasan Volkan Ege

Hacettepe University, Ankara, Turkey (Türkiye)
orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2025 in Journal of Gynecologic Oncology
Verified
Journal Article
Open access
PDF file
HEHasan Volkan Ege
Hasan Volkan Ege
MCMURAT CENGIZ
MURAT CENGIZ
Nezih AkkapuluNezih Akkapulu
Nezih Akkapulu
UAUtku Akgör
Utku Akgör
MGMurat Gultekin
Murat Gultekin
DBDerman Basaran
Derman Basaran
Ege HV, et al. J Gynecol Oncol. 2024 Sep;36:e32. https://doi.org/10.3802/jgo.2025.36.e32

15 April 2026 in European Journal of Cancer
Verified
Journal Article
Open access
Claudia MarchettiClaudia Marchetti
Claudia Marchetti
MGMurat Gultekin
Murat Gultekin
CSCarolina Maria Sassu
Carolina Maria Sassu
FPFrançois Planchamp
François Planchamp
LELaura Burney Ellis
Laura Burney Ellis
Maria KyrgiouMaria Kyrgiou
Maria Kyrgiou
Lynch syndrome (LS) is a hereditary condition associated with an increased susceptibility to developing cancer, primarily colorectal and gynaecological cancer (endometrial cancer and ovarian cancer). The European Society of Gynaecological Oncology (ESGO) nominated fifteen practicing multidisciplinary clinicians with expertise in this field and ten gynaecological and oncological fellows with interest in the topics to develop evidence-based statements, sharing and standardizing the management of LS carriers. Published evidence was integrated with clinical experience to reach Consensus Statements through anonymous voting. In this Consensus, thirty-one statements based on the best available evidence and expert agreement are offered. They focused on genetic and cancer risk counseling principles, screening procedures, risk-reducing surgical and medical strategies, and address emerging topics such as reproductive issues for LS carriers, which are important in current practice. This manuscript reports the Statements that reached a consensus, their voting results, and a summary of supporting evidence.

29 January 2026 in Vaccines
Verified
Journal Article
Open access
PDF file
UAUtku Akgör
Utku Akgör
BTBİLAL ESAT TEMİZ
BİLAL ESAT TEMİZ
MCMURAT CENGIZ
MURAT CENGIZ
HEHasan Volkan Ege
Hasan Volkan Ege
EJElmar A Joura
Elmar A Joura
MGMurat Gultekin
Murat Gultekin
Next-generation human papillomavirus (HPV) vaccines encompass newly licensed and emerging formulations that employ alternative production platforms, expanded valency, or novel antigenic targets beyond conventional L1-based vaccines. These vaccines aim to address affordability challenges, supply limitations, and suboptimal vaccination coverage, particularly in low- and middle-income countries. This review aggregates current clinical, immunological, and programme-related evidence on newly licensed vaccines, including the World Health Organization (WHO)-prequalified bivalent formulations (Cecolin® and Walrinvax®), the quadrivalent Cervavac®, and the Escherichia coli-derived nonavalent Cecolin 9®, which received national licensure in 2025. Additionally, emerging high-valency candidates in Phase I–III trials—9-valent, 11-valent, and 14-valent formulations—are critically assessed. Clinical trials demonstrate that next-generation HPV vaccines provide robust protection; for example, Cecolin® showed 100% efficacy against HPV-16/18-associated high-grade squamous intraepithelial lesions (HSIL) and up to 97.8% efficacy against persistent HPV infection, while Walrinvax® demonstrated 78.6% protection against CIN2+ lesions. Cervavac® showed non-inferior immunogenicity compared with established vaccines. While comparative analyses of efficacy, immunogenicity, and safety indicate that these vaccines are strong alternatives to established products, robust long-term effectiveness and real-world impact data remain essential before full clinical equivalence can be definitively established. Advances in L2-based platforms further aim to broaden cross-type protection, simplify manufacturing, and enable thermostable formulations, thereby enhancing applicability in resource-limited settings. Economic evaluations demonstrating favorable cost-effectiveness emphasize the essential role of next-generation vaccines in improving access and reducing inequity. Overall, innovations in valency, technology, and delivery strategies have the potential to significantly expand global HPV prevention coverage and accelerate progress toward cervical cancer elimination.

11 April 2026 in Pakistan Journal of Medical Sciences
Verified
Journal Article
Open access
PDF file
GEGökçen Ege
Gökçen Ege
HEHasan Volkan Ege
Hasan Volkan Ege
HKHüseyin Levent Keskin
Hüseyin Levent Keskin
AYAyşe Filiz Yavuz
Ayşe Filiz Yavuz
Objective: To determine the frequency and clinicopathological features of incidental premalignant and malignant gynecological lesions detected after hysterectomies performed for benign indications, and to identify associated risk factors. Methodology: This retrospective study reviewed 1,047 hysterectomies performed for benign conditions at a tertiary center in Ankara, Turkiye, over a ten years period (January 2006-December 2015). Demographic characteristics, preoperative assessments, surgical indications, and histopathological outcomes were analyzed. Incidental lesions were defined as pre-malignant or malignant pathologies identified postoperatively without prior clinical suspicion. Statistical analyses were performed using chi-square and t-tests. Results: Incidental pre-malignant or malignant lesions were identified in 6% (n=63) of cases, including cervical dysplasia/HSIL (0.9%), borderline ovarian tumors (1.1%), endometrial adenocarcinoma (0.5%), leiomyosarcoma (0.5%), and high-grade serous ovarian carcinoma (0.6%). Postmenopausal women had a significantly higher incidence than premenopausal women (9.2% vs. 3.8%, p<0.001). Patients with incidental findings were older than those with benign pathology (55.4 ± 11.2 vs. 52.7 ± 9.6 years, p=0.034). Larger myomas were associated with uterine sarcoma (172 ± 92 mm vs. 71 ± 39 mm, p<0.001). Ovarian malignancies were detected in 2.4% of cases without suspicious ultrasound features and in 14.8% of cases with ≥2 malignancy criteria (p=0.013). Serous tubal intraepithelial carcinoma (STIC) was identified in 0.28% (n=3). Conclusion: Incidental pre-malignant or malignant lesions were present in 6% of hysterectomies performed for benign indications. Age, menopausal status, myoma size, and suspicious imaging features were significant predictors. Preoperative evaluation may not completely exclude the possibility of occult pathology; therefore, this risk should be discussed during preoperative counseling.

31 January 2026 in Vaccines
Verified
Journal Article
Open access
PDF file
HEHasan Volkan Ege
Hasan Volkan Ege
BTBİLAL ESAT TEMİZ
BİLAL ESAT TEMİZ
MGMihaela Grigore
Mihaela Grigore
LELaura Burney Ellis
Laura Burney Ellis
Sarah Joanne BowdenSarah Joanne Bowden
Sarah Joanne Bowden
Maria KyrgiouMaria Kyrgiou
Maria Kyrgiou
Background/Objectives: Persistent human papillomavirus (HPV) infection can lead to malignancies of the cervix, vulva, vagina, penis, anus, and oropharynx. The increasing incidence of HPV-related head and neck cancers has raised concerns regarding potential occupational exposure and transmission risks among healthcare workers. This study aimed to systematically evaluate the evidence on occupational HPV transmission in healthcare settings. Methods: A systematic review of the literature was conducted using three electronic databases (PubMed, Scopus, and Web of Science) from inception to August 2025, following PRISMA 2020 guidelines. A total of 34 studies met the inclusion criteria and were included in the review. Expert opinions and practical recommendations from members of the European Society of Gynaecological Oncology (ESGO) Prevention Committee were included to support interpretation of the results. Results: The available literature on occupational HPV transmission was limited, with a paucity of high-quality studies. Nevertheless, existing data suggest a potential occupational risk, particularly during aerosol or smoke-generating procedures performed for cervical intraepithelial neoplasia or cervical cancer. Several studies reported the detection of HPV DNA in surgical smoke or on instruments used during such procedures, indicating possible exposure among healthcare workers. Conclusions: Although current evidence is insufficient to definitively classify HPV infection as an occupational disease, available data indicate a potential exposure risk for healthcare workers involved in HPV-related procedures. Preventive measures, like personal protective equipment, should be emphasized. HPV vaccination has been recommended by some professional societies for healthcare workers performing gynecological procedures, though further research is needed to evaluate vaccine efficacy beyond the standard age range and its cost-effectiveness in this context.

2 June 2026 in Annals of Surgical Oncology
Verified
Journal Article
Open access
MCMURAT CENGIZ
MURAT CENGIZ
OZOnur Can Zaim
Onur Can Zaim
BTBİLAL ESAT TEMİZ
BİLAL ESAT TEMİZ
AKAnil Karakilinc
Anil Karakilinc
OYOmer Alp Yavuz
Omer Alp Yavuz
DBDerman Basaran
Derman Basaran
Background: To compare outcomes between older (≥ 70 years) and younger (< 70 years) patients with surgically treated endometrial cancer, evaluating the Prognostic Nutritional Index (PNI), Systemic Immune-Inflammation Index (SII), and Age-Adjusted Charlson Comorbidity Index (ACCI). Methods: This retrospective cohort study included 319 patients who underwent surgery at a tertiary center (2014–2024). Demographics, pathology, treatment, and outcomes were analyzed. Perioperative morbidity was graded (Clavien–Dindo). Frailty (ACCI), PNI, and SII were assessed. Overall survival and disease-specific survival were analyzed in parallel; Kaplan–Meier analyses were performed overall and stratified by stage and histology. Major morbidity was analyzed with multivariable logistic regression. Results: Of 319 patients, 93 (29.2%) were aged ≥ 70 years. Older patients more frequently exhibited high-grade histology, advanced stage, ASA III–IV status, high ACCI, and low PNI. Admissions to the intensive care unit were higher in older patients, but major morbidity (4.3% vs. 3.5%; p = 0.60) and 30-day mortality (1.1% vs. 0.9%; p = 0.60) were comparable between groups. Low PNI demonstrated moderate discriminatory ability for major complications. In multivariable analysis, low PNI (odds ratio 5.78; p = 0.012) and ASA III–IV (odds ratio 3.89; p = 0.047) were independently associated with major morbidity, whereas age ≥ 70 was not. For overall survival, higher PNI remained protective (hazard ratio 0.48 per 5-point increase; p < 0.001) and ASA III–IV predicted worse outcomes (hazard ratio 3.80; p = 0.002); however, chronological age was not an independent predictor. Conclusion: Older age is associated with more aggressive tumor biology but not with higher rates of major complications. PNI and ASA class are independent predictors of major morbidity and survival and should be integrated into perioperative risk stratification rather than using chronological age alone.